PT-141, also called bremelanotide, is a melanocortin agonist studied in sexual-function research, including controlled trials in a narrowly defined clinical population.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Melanocortin-receptor agonist
PT-141 is the development designation for bremelanotide, a synthetic cyclic peptide related to alpha-MSH. It is distinct from Melanotan II despite their shared melanocortin research lineage. A catalog vial is not interchangeable with the pharmaceutical formulation studied in the clinical development program.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
PT-141 activates melanocortin receptors, including receptor systems involved in central sexual responses. Early work linked animal erectile responses to hypothalamic neuronal activation and also reported human physiological effects. Such observations support a central signaling hypothesis without establishing that every reported effect has a single receptor or circuit.
Early translational work combined animal observations, markers of hypothalamic activation, and human erectile measurements. These findings concern pathway activity and acute responses, rather than proof of broadly improved sexual function across populations. [1]
The two placebo-controlled RECONNECT trials evaluated a defined bremelanotide formulation in premenopausal women with hypoactive sexual desire disorder. Desire and related-distress scores improved relative to placebo; nausea, flushing, and headache were more frequent with active treatment. [2]
An open-label extension followed eligible participants from the controlled trials. Symptom changes and tolerability were described, but only a subset completed the extension. The absence of a concurrent placebo group and selective participation weaken causal interpretation of longer-term results. [3]
Study topics describe the cited models, not established benefits of this catalog material.
The controlled clinical program provides stronger evidence than the early physiological studies, but only for its specified population, formulation, and endpoints. Findings about desire and distress do not establish an unrestricted effect on sexual performance, fertility, or relationship quality, and should not be generalized across sexes or diagnoses.
Distinguish the named molecule from a finished medicine and distinguish clinical endpoints from mechanistic hypotheses. Treatment-related adverse effects and extension-study attrition are part of the evidence. None of these publications establishes WYZ Labs product equivalence, purity, manufacturing quality, or batch-specific documentation.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Early translational report of central melanocortin activity and erectile physiology.
RECONNECT trials of a defined clinical formulation in premenopausal women with HSDD.
Follow-up of selected trial participants; substantial noncompletion and no concurrent placebo comparison.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
